• 1
    Withrow SJ, David VM. Withrow & MacEwen's Small Animal Clinical Oncology. In: Withrow SJ, David VM, eds. Cancer Chemotherapy, 4 ed. St. Louis, MO: Saunders, an imprint of Elsevier Inc; 2007:784.
  • 2
    Tomiyasu H, Takahashi M, Fujino Y, et al. Gastrointestinal and hematologic adverse events after administration of vincristine, cyclophosphamide, and doxorubicin in dogs with lymphoma that underwent a combination multidrug chemotherapy protocol. J Vet Med Sci 2010;72:13911397.
  • 3
    Tomomasa T, Miyazawa R, Kato M, et al. Prolonged gastrointestinal dysmotility in a patient with hemophagocytic lymphohistiocytosis treated with vincristine. Dig Dis Sci 1999; 44:17551757.
  • 4
    Thamm DH, Vail DM. Aftershocks of cancer chemotherapy: Managing adverse effects. J Am Anim Hosp Assoc 2007; 43:17.
  • 5
    Curran MP, Robinson DM. Mosapride in gastrointestinal disorders. Drugs 2008; 68:981991.
  • 6
    Yoshida N, Ito T, Karasawa T, et al. AS-4370, a new gastrokinetic agent, enhances upper gastrointestinal motor activity in conscious dogs. J Pharmacol Exp Ther 1991;257:781787.
  • 7
    Tsukamoto A, Ohno K, Tsukagoshi T, et al Real-time ultrasonographic evaluation of canine gastric motility in the postprandial state. J Vet Med Sci 2011;73:11331138.
  • 8
    Veterinary Co-operative Oncology Group. Common Terminology Criteria for Adverse Events (VCOG-CTCAE) following chemotherapy or biological antineoplastic therapy in dogs and cats v1.0. Vet Comp Oncol 2004;2:195213.
  • 9
    Garewal HS, Dalton WS. Metoclopramide in vincristine-induced ileus. Cancer Treat Rep 1985;69:13091311.
  • 10
    Yatera S, Koujitani T, Yasuba M, et al. Toxicity study of mosapride citrate (3). Thirteen-week repeated dose oral toxicity study in Beagle dogs. Jpn Pharmacol Ther 1993;21:5773.